vs

Side-by-side financial comparison of Opera Ltd (OPRA) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

REPLIGEN CORP is the larger business by last-quarter revenue ($197.9M vs $142.7M, roughly 1.4× Opera Ltd). Opera Ltd runs the higher net margin — 12.8% vs 6.7%, a 6.1% gap on every dollar of revenue.

Opera is a multinational technology corporation headquartered in Oslo, Norway, with additional offices in Europe, China, and Africa. Opera offers a range of products and services that include PC and mobile web browsers, GameMaker and gaming portals, the Opera News content recommendation products, the Opera Ads platform, and a number of Web3 and e-commerce products and services. The company's total user base is 296 million monthly active users.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

OPRA vs RGEN — Head-to-Head

Bigger by revenue
RGEN
RGEN
1.4× larger
RGEN
$197.9M
$142.7M
OPRA
Higher net margin
OPRA
OPRA
6.1% more per $
OPRA
12.8%
6.7%
RGEN

Income Statement — Q1 FY2025 vs Q4 FY2025

Metric
OPRA
OPRA
RGEN
RGEN
Revenue
$142.7M
$197.9M
Net Profit
$18.3M
$13.3M
Gross Margin
52.5%
Operating Margin
14.8%
9.0%
Net Margin
12.8%
6.7%
Revenue YoY
13.6%
Net Profit YoY
143.9%
EPS (diluted)
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPRA
OPRA
RGEN
RGEN
Q4 25
$197.9M
Q3 25
$188.8M
Q2 25
$182.4M
Q1 25
$142.7M
$169.2M
Q4 24
$174.1M
Q3 24
$154.9M
Q2 24
$211.6M
$154.1M
Q1 24
$151.3M
Net Profit
OPRA
OPRA
RGEN
RGEN
Q4 25
$13.3M
Q3 25
$14.9M
Q2 25
$14.9M
Q1 25
$18.3M
$5.8M
Q4 24
$-30.3M
Q3 24
$-654.0K
Q2 24
$34.1M
$3.3M
Q1 24
$2.1M
Gross Margin
OPRA
OPRA
RGEN
RGEN
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Q1 24
49.5%
Operating Margin
OPRA
OPRA
RGEN
RGEN
Q4 25
9.0%
Q3 25
8.9%
Q2 25
7.6%
Q1 25
14.8%
3.9%
Q4 24
-17.7%
Q3 24
-5.1%
Q2 24
19.6%
1.0%
Q1 24
1.3%
Net Margin
OPRA
OPRA
RGEN
RGEN
Q4 25
6.7%
Q3 25
7.9%
Q2 25
8.2%
Q1 25
12.8%
3.4%
Q4 24
-17.4%
Q3 24
-0.4%
Q2 24
16.1%
2.2%
Q1 24
1.4%
EPS (diluted)
OPRA
OPRA
RGEN
RGEN
Q4 25
$0.24
Q3 25
$0.26
Q2 25
$0.26
Q1 25
$0.10
Q4 24
$-0.55
Q3 24
$-0.01
Q2 24
$0.06
Q1 24
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPRA
OPRA
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$2.1B
Total Assets
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPRA
OPRA
RGEN
RGEN
Q4 25
$767.6M
Q3 25
$748.7M
Q2 25
$708.9M
Q1 25
$697.2M
Q4 24
$757.4M
Q3 24
$784.0M
Q2 24
$809.1M
Q1 24
$780.6M
Total Debt
OPRA
OPRA
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
OPRA
OPRA
RGEN
RGEN
Q4 25
$2.1B
Q3 25
$2.1B
Q2 25
$2.1B
Q1 25
$2.0B
Q4 24
$2.0B
Q3 24
$2.0B
Q2 24
$2.0B
Q1 24
$2.0B
Total Assets
OPRA
OPRA
RGEN
RGEN
Q4 25
$2.9B
Q3 25
$2.9B
Q2 25
$2.9B
Q1 25
$2.9B
Q4 24
$2.8B
Q3 24
$2.8B
Q2 24
$2.9B
Q1 24
$2.8B
Debt / Equity
OPRA
OPRA
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OPRA
OPRA
RGEN
RGEN
Operating Cash FlowLast quarter
$25.7M
Free Cash FlowOCF − Capex
$17.6M
FCF MarginFCF / Revenue
8.9%
Capex IntensityCapex / Revenue
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OPRA
OPRA
RGEN
RGEN
Q4 25
$25.7M
Q3 25
$48.1M
Q2 25
$28.6M
Q1 25
$15.0M
Q4 24
$39.2M
Q3 24
$49.3M
Q2 24
$42.2M
Q1 24
$44.7M
Free Cash Flow
OPRA
OPRA
RGEN
RGEN
Q4 25
$17.6M
Q3 25
$43.4M
Q2 25
$21.5M
Q1 25
$11.4M
Q4 24
$33.6M
Q3 24
$42.3M
Q2 24
$37.4M
Q1 24
$36.4M
FCF Margin
OPRA
OPRA
RGEN
RGEN
Q4 25
8.9%
Q3 25
23.0%
Q2 25
11.8%
Q1 25
6.8%
Q4 24
19.3%
Q3 24
27.3%
Q2 24
24.3%
Q1 24
24.0%
Capex Intensity
OPRA
OPRA
RGEN
RGEN
Q4 25
4.1%
Q3 25
2.5%
Q2 25
3.9%
Q1 25
2.1%
Q4 24
3.2%
Q3 24
4.5%
Q2 24
3.1%
Q1 24
5.5%
Cash Conversion
OPRA
OPRA
RGEN
RGEN
Q4 25
1.93×
Q3 25
3.23×
Q2 25
1.92×
Q1 25
2.57×
Q4 24
Q3 24
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons